TATUM Bioscience Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Latest Deal Amount
  • $40K

  • Investors
  • 14

TATUM Bioscience General Information

Description

Developer of multi-pathway immune engagers designed to stimulate antitumor immunity in cancers with limited response to checkpoint inhibitors. The company develops bioengineered nanofilaments that combine checkpoint blockade, innate immune activation, and T-cell stimulation, enabling systemic immune responses in patients with solid tumors, initially targeting colorectal cancer with liver metastases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3000 Boulevard de l'Université, Building P1-CTA
  • Sherbrooke, Quebec J1K 0A5
  • Canada
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 3000 Boulevard de l'Université, Building P1-CTA
  • Sherbrooke, Quebec J1K 0A5
  • Canada

TATUM Bioscience Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TATUM Bioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Accelerator/Incubator 24-Sep-2025 $40K Completed Pre-Clinical Trials
9. Accelerator/Incubator 01-Jan-2025 Completed Generating Revenue
8. Later Stage VC 30-Nov-2024 Completed Generating Revenue
7. Accelerator/Incubator 21-May-2024 Completed Startup
6. Later Stage VC 27-Mar-2024 Completed Startup
5. Early Stage VC 17-May-2021 Completed Startup
4. Accelerator/Incubator 01-Jan-2021 Completed Startup
3. Early Stage VC 10-Mar-2020 Completed Startup
2. Grant 03-Dec-2019 $3K Completed Startup
1. Accelerator/Incubator Completed Startup
To view TATUM Bioscience’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

TATUM Bioscience Patents

TATUM Bioscience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023405587-A1 Therapeutic bacteriophage displaying cancer cell targeting moieties along with cytokines for the treatment of cancer Pending 01-Dec-2022
EP-4627066-A1 Therapeutic bacteriophage displaying cancer cell targeting moieties along with cytokines for the treatment of cancer Pending 01-Dec-2022
WO-2024113057-A1 Therapeutic bacteriophage displaying cancer cell targeting moieties along with cytokines for the treatment of cancer Inactive 01-Dec-2022
JP-2026094386-A Live biopharmaceuticals that secrete synthetic bacteriophages in cancer treatment Pending 07-Oct-2020
CA-3195020-A1 Live biotherapeutics secreting synthetic bacteriophages in the treatment of cancer Pending 07-Oct-2020 C12N15/70
To view TATUM Bioscience’s complete patent history, request access »

TATUM Bioscience Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TATUM Bioscience Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Startup TNT Angel Group
MassBio Accelerator/Incubator
Capital BioVentures Accelerator/Incubator Minority
CQDM Not-For-Profit Venture Capital Minority
Investissement Quebec PE/Buyout Minority
You’re viewing 5 of 14 investors. Get the full list »

TATUM Bioscience FAQs

  • When was TATUM Bioscience founded?

    TATUM Bioscience was founded in 2019.

  • Where is TATUM Bioscience headquartered?

    TATUM Bioscience is headquartered in Sherbrooke, Canada.

  • What is the size of TATUM Bioscience?

    TATUM Bioscience has 6 total employees.

  • What industry is TATUM Bioscience in?

    TATUM Bioscience’s primary industry is Drug Discovery.

  • Is TATUM Bioscience a private or public company?

    TATUM Bioscience is a Private company.

  • What is TATUM Bioscience’s current revenue?

    The current revenue for TATUM Bioscience is .

  • How much funding has TATUM Bioscience raised over time?

    TATUM Bioscience has raised $2.66M.

  • Who are TATUM Bioscience’s investors?

    Startup TNT, MassBio, Capital BioVentures, CQDM, and Investissement Quebec are 5 of 14 investors who have invested in TATUM Bioscience.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process